By John Vandermosten, CFA
NASDAQ:LPCN
READ THE FULL LPCN RESEARCH REPORT
On May 9, 2022 Lipocine LPCN filed its Form 10-Q and posted its earnings release for the quarter ending March 31, 2022.
Highlights for the first quarter 2022 and to-date include:
TLANDO US commercialization licensing agreement with Antares Pharma - October 2021
FDA grants Fast Track Designation to LPCN 1144 - November 2021
First patient dosed in Phase II, LPCN 1148 in liver cirrhosis - December 2021
Presentations at 2022 NASH-TAG Conference - January 2022
Publication of Phase III results for TLANDO - January 2022
Licensee Antares TLANDO NDA resubmission accepted - February 2022
Regulatory guidance on LPCN 1144 in non-cirrhotic NASH - March 2022
Lipocine generated no revenues in the first quarter. It reported net loss of ($3.5) million, or ($0.04) per diluted share.
For the quarter ending March 31, 2022 and versus the same ending March 31, 2021:
Revenues were zero in both periods;
Research & Development expense totaled $1.9 million, up 19% from $1.6 million, driven by higher contract research organization (CRO) expenses for LPCN 1148, pharmacokinetic and food effect studies for LPCN 1107 and 1154, greater manufacturing scale-up costs for LPCN 1111 and higher personnel expenses;
General & Administrative expenses were $1.2 million, falling 19% from $1.5 million primarily due to lower legal costs relating to the Clarus lawsuit, and lower personnel costs, partially offset by higher professional fees, consulting fees, proxy solicitation expenses and corporate insurance costs;
Total other net expense was ($0.4) million, compared to ($0.3) million, as increases in interest and investment income were more than offset by an increase in unrealized loss on the warrant liability;
Net loss was ($3.5) million or ($0.04) per share compared with net loss of ($3.4) million or ($0.04) per share, respectively.
At quarter's end, marketable securities, cash and equivalents totaled $42.0 million. Cash burn for 1Q:22 was ($3.9) million, compared with ($4.1) million in 1Q:21. During the three month period, Lipocine repaid $0.8 million of debt and received $0.2 million from option exercises for a net cash change vs. year end 2021 of ($2.8) million.
TLANDO Licensing Agreement with Antares Pharma
On October 18th of last year Lipocine announced that it had entered into a licensing agreement with Antares Pharma. The agreement is for commercialization of TLANDO in the US and includes the following terms:
Up to $21 million in licensing fees;
$11 million payable immediately;
$10 million in future payments subject to certain conditions;
Commercial sales payments based on milestones up to $160 million;
Tiered royalties on net sales from mid-teens up to 20%;
Antares responsible for all commercialization, post-marketing studies, and sourcing of TLANDO in US;
Also included is Antares option to license TLANDO XR; if exercised
Antares gains license to develop and commercialize TLANDO XR in the US;
Lipocine would receive $4 million in license fees;
Up to $35 million in clinical and regulatory milestone payments;
Tiered royalties on net sales from mid-teens to 20%
Antares responsible for all clinical development costs, regulatory filings, commercialization and post-marketing activities.
On April 1, 2022, Lipocine and Antares amended the Tlando XR option agreement, extending it by three months to June 30, 2022 from the original March 31 date. Tlando XR is the next generation of Tlando which allows for once daily dosing for the TRT therapy. In return for the extension, Antares paid Lipocine $500,000 which will be credited towards the $4 million license fee required if Antares wishes to execute the license.
Lipocine retains all rights to rest of world and non-testosterone replacement therapy indications for both TLANDO and TLANDO XR. We update our model to reflect the terms of this arrangement and assume that Antares will exercise its option to advance TLANDO XR.
LPCN 1144 for Treatment of Non-Cirrhotic NASH
With the commercialization of TLANDO underway with Antares, LPCN 1144 moves into pole position at Lipocine. The company will shift its primary attention towards LPCN 1144 and an upcoming End of Phase II (EoP2) meeting with the FDA to determine trial design. We anticipate that a clear path forward for LPCN 1144 will be provided to stakeholders later this year.
Regulatory Guidance on LPCN 1144
On March 1, 2022, Lipocine provided an update on its Type C meeting with the FDA regarding LPCN 1144's development. The FDA provided written response acknowledging that LPCN 1144's NDA would be submitted via 505(b)(2) regulatory pathway, that no additional nonclinical studies are needed to support the submission, and that Lipocine's Phase II LiFT study's multicomponent primary surrogate endpoint is acceptable for seeking approval under accelerated approval. The FDA recommended Lipocine either conduct a separate dose-ranging study prior to Phase III or evaluate multiple doses in the Phase III study and that the aforementioned multicomponent primary surrogate endpoint is acceptable. The FDA recommended Phase III study duration of 72 weeks. The FDA also recommended that Lipocine submit an updated Phase III protocol and discuss details further in an EoP2 which is expected to take place in 3Q:22.
Next Steps
Now that selected 36-week biopsy data has been presented to stakeholders and with the Fast Track Designation in its back pocket, Lipocine's next steps are to prepare a presentation for a scientific and medical conference and complete the extension study. With feedback from its Type C meeting with the FDA, Lipocine is now charged with redesigning and submitting an updated Phase III protocol to the FDA, and scheduling an EoP2 meeting with the FDA. In response to FDA guidance, Lipocine must decide whether it wishes to conduct a preliminary dose-ranging study, or to incorporate dose-ranging into the design of its Phase III trial. Management has voiced its desire to seek a partner to advance LPCN 1144 into a registrational study.
Clarus Settlement
In mid-2021, Lipocine settled its claims related to the patent infringement litigation with Clarus for $4.0 million as described in our August 6, 2021 report. $2.5 million was paid immediately, followed by a promised $1.0 million payment in July 2022 and $500,000 in July 2023. On April 29, 2022, Lipocine modified the agreement in its favor by consenting to pay Clarus $1.25 million in May 2022, with no additional payments required thereafter. This provides non-discounted savings of $250,000 over the original agreement and settles the financial aspect of this matter.
Milestones
TLANDO
NDA filed for TLANDO - February 2020
Tentative approval of TLANDO - December 2020
TLANDO licensing agreement with Antares - October 2021
TLANDO full approval - March 28, 2022
First sales late 2Q:22
LPCN 1144
Presentation of 36-week LiFT study, biopsy data to investors - August 2021
End of Phase II meeting with FDA - 2H:21
Grant of Fast Track Designation for LPCN 1144 - November 2021
Type C meeting results for LPCN 1144 - March 2022
LPCN 1144 End-of-Phase II meeting request - April 2022
Open Label Extension (OLE) topline results May 2022
LPCN 1144 End-of-Phase II meeting - 3Q:22
Explore business development partnering 2022/2023
LPCN 1148
IND clearance for Phase II study of LPCN 1148 - May 2020
Male cirrhosis trial first subject dosed for LPCN 1148 - 4Q:21
Enrollment completion - 3Q:22
Topline 24-week results - 1Q:23
LPCN 2101 IND in epilepsy - 2022
Topline announcement for PK study for LPCN 1154 - 4Q:21/1Q:22
Launch Phase IIa proof of concept Post-Partum Depression (PPD) trial - 4Q:21
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
1. Lipocine Corporate Presentation January 2022
Read this article:
LPCN: First Quarter 2022 Financial and Operational Results - Benzinga
- Global Testosterone Replacement Therapy Market Size To Worth USD 2.93 Billion By 2033 | CAGR Of 4.0% - Yahoo Finance - April 21st, 2024
- Testosterone replacement therapy: Yes or no - MD Anderson Cancer Center - January 6th, 2024
- 5 Best Testosterone Replacement Therapy Services 2023 - Men's Health - January 6th, 2024
- How Much Is Testosterone? The Cost of Replacement Therapy - Hone Health - January 6th, 2024
- Testosterone Replacement Therapy - Department of Urology - January 6th, 2024
- Testosterone Replacement Therapy for Low T - Ageless Men's Health - January 6th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 6th, 2024
- TRAVERSE Trial: Insights into Testosterone Replacement Therapy Safety - BNN Breaking - January 6th, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 6th, 2024
- Testosterone Replacement Therapy (TRT): Is It Right For You? - December 2nd, 2023
- Low Testosterone (Low T): Causes, Symptoms & Treatment - Cleveland Clinic - March 28th, 2023
- LowTCenter: Men's Health Clinic for Testosterone Replacement - March 28th, 2023
- Testosterone Replacement Therapy for Men | SynergenX - March 28th, 2023
- Male hypogonadism - Diagnosis and treatment - Mayo Clinic - February 6th, 2023
- Testosterone Replacement Therapy (TRT) Experts | Optimale - December 2nd, 2022
- Testosterone Replacement Therapy Clinic - EHormones MD - November 24th, 2022
- Options to Increase Your Testosterone - Healthline - November 16th, 2022
- Masculinizing hormone therapy - Wikipedia - October 29th, 2022
- Testosterone: What It Is and How It Affects Your Health - October 13th, 2022
- Testosterone What It Does And Doesn't Do - Harvard Health - October 13th, 2022
- Cork woman felt like she lost part of herself after going into menopause aged 27 - RSVP Live - October 13th, 2022
- The Global Testosterone Replacement Therapy Market is - October 4th, 2022
- Hypogonadism in Men | Endocrine Society - October 4th, 2022
- The One Thing This Doctor Says Is A Game Changer When It Comes To Hormones And Aging - TravelAwaits - October 4th, 2022
- Shirley Ballas on her difficult experience with menopause - Good Housekeeping - October 4th, 2022
- Foods That Boost Testosterone: 7 Options and How They Work - Healthgrades - October 4th, 2022
- Dr. Roach: Testosterone injections most likely led to severe stroke - Detroit News - October 4th, 2022
- What To Know About Perimenopause, And How To Manage Symptoms Once They Kick In - The Zoe Report - October 4th, 2022
- CORRECTION -- Marius Pharmaceuticals Receives FDA Approval of KYZATREX, an Oral Testosterone Replacement Therapy - GlobeNewswire - September 25th, 2022
- Testosterone replacement therapy - PubMed - September 16th, 2022
- Risks of testosterone replacement therapy in men - PMC - September 16th, 2022
- The Global Testosterone Replacement Therapy Market is expected to grow by $ 402.87 mn during 2022-2026, accelerating at a CAGR of 3.1% during the... - September 16th, 2022
- Testosterone injections most likely led to a very severe stroke - The Independent - September 16th, 2022
- Best DHEA Supplement (2022 Updated) - The Island Now - September 16th, 2022
- Testosterone Replacement Therapy in the Aged Male: Monitoring Patients | IJGM - Dove Medical Press - September 8th, 2022
- ROACH: Testosterone injections most likely led to a very severe stroke - New Castle News - September 8th, 2022
- Perform Your Best With Comprehensive Bloodwork - duPont REGISTRY News - September 8th, 2022
- What I Learned When I Stopped Testosterone Replacement Therapy |... - Cushing's Disease News - August 30th, 2022
- From White Plains Hospital: Feeling the Effects of Man-o-pause? - theLoop - August 30th, 2022
- SARMs Before And After Results Real SARM Results And Users Review In 2022 - Outlook India - August 30th, 2022
- Larry Wheels Stops Using Steroids: "I Am Going To Be On Testosterone Replacement Therapy" Fitness Volt - Fitness Volt - August 22nd, 2022
- Hormone Replacement Therapy for Men: What to Know - Healthline - August 14th, 2022
- Testosterone Replacement Therapy Market Trends, Analysis, Demand and Global Industry Research Report, Region, and Segment Forecasts 2028 - Digital... - August 14th, 2022
- Cycling and HRT: How will it affect me? - Cyclist - August 14th, 2022
- 6 LGBTQ2S+ musicians celebrate the artists who came before them - CBC.ca - August 14th, 2022
- 'I kept thinking I was having a heart attack but it was the perimenopause' - iNews - July 27th, 2022
- Obese women with high intake of vitamin C and B6 associated with lower breast cancer risk cohort study - NutraIngredients-Asia - July 27th, 2022
- Testosterone Replacement Therapy Market | Incredible Possibilities, Growth, Trend, Opportunities Detailed Analysis and Forecast to 2030 Travel... - July 19th, 2022
- Low on the Male Hormone? 5 Effective Ways to Boost It - Times Square Chronicles - July 19th, 2022
- Ostarine MK-2866 | Review, Alternatives,Side Effects and Results-Health News - Firstpost - July 19th, 2022
- Trans teens: We need to be heard, counted. In Michigan, the backlash is harsh - Bridge Michigan - July 19th, 2022
- Testosterone Therapy Improves Erectile Function and Libido in ... - July 11th, 2022
- Low Testosterone and What You Can Do About It - The Epoch Times - July 11th, 2022
- How Long Does It Take to Feel the Benefits of Testosterone Replacement ... - July 3rd, 2022
- TRT Testosterone Replacement Therapy Clinic - Peter Uncaged MD - July 3rd, 2022
- Men have it too - The Hans India - July 3rd, 2022
- New guidelines for menopause care say women should be offered personalised treatment including diet and HRT - iNews - July 3rd, 2022
- Head-To-Head Contrast: Biogen (NASDAQ:BIIB) and Clarus Therapeutics (NASDAQ:CRXT) - Defense World - July 3rd, 2022
- Im a GP heres the truth behind Davina McCalls claims about HRT and dementia... - The Sun - July 3rd, 2022
- How To Spot The Best Clinic For Your Hormone Replacement Therapy - My MMA News.com - June 22nd, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 22nd, 2022
- Boyfriend has been secretly taking testosterone tablets and I worry he may go sterile... - The Sun - June 22nd, 2022
- Sex and aging: Overview, stats, and maintaining satisfaction - Medical News Today - June 22nd, 2022
- Once a Taboo Topic, Menopause Is (Finally) Having Its Wellness Moment - Vogue - June 4th, 2022
- Caitlyn Jenner can still hit golf ball nearly 300 yards after transitioning to female - Washington Times - June 4th, 2022
- Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Receives $6.88 Consensus PT from Analysts - Defense World - June 4th, 2022
- Juvenile Macular Degeneration Treatment Market Set to Grow According to Forecasts 2020 2030 Industrial IT - Industrial IT - June 4th, 2022
- Testosterone Replacement Therapy Market 2022 to 2028 Global Industry Analysis, Growth, Trends and Forecast Queen Anne and Mangolia News - Queen Anne... - May 15th, 2022
- Being trans and starting HRT - The Advocate - May 15th, 2022
- DHEA Levels and Their Role in Fertility for Functional Medicine Patients - Digital Journal - May 15th, 2022
- LIPOCINE INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q) - Marketscreener.com - May 15th, 2022
- No, red light therapy isnt a medically approved treatment for increasing testosterone - ABC10.com KXTV - May 2nd, 2022
- Tucker Carlsons answer to masculinitys supposed crisis? Testicle tanning - The Guardian - April 19th, 2022
- Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing - PR Newswire - April 19th, 2022
- Gilbert Gottfrieds myotonic dystrophy: 5 things to know about the rare genetic disorder - cleveland.com - April 19th, 2022
- Lia Thomas started a conversation about transgender rights. It's time we dive into it. - The Emory Wheel - April 19th, 2022
- Who are the teens at the center of the legal fight over Alabamas law banning transgender treatment? - AL.com - April 19th, 2022
- In Venice, a Young Boatman Steers a Course of His Own - The New York Times - April 19th, 2022
- Female athletes are as capable as male athletes | Opinion | kansan.com - The University Daily Kansan - April 19th, 2022
- FDA Approves Oral Testosterone Replacement Therapy for Hypogonadism - Pharmacy Times - April 6th, 2022